DYRK1A and myocardial infarction: Based on these findings, we tested the DYRK1A inhibitor Leucettinib-92 (LCTB-92) in a mouse model of ischemia-reperfusion (I/R) myocardial infarction (MI), where it improved heart function and increased cardiomyocyte cycling.